Double-Layer Controlled-Release Tablets for Serotonin Deficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations for treating serotonin deficiency in the Central Nervous System with tryptophan (Trp) and its metabolites, such as 5-hydroxytryptophan (5-HTP), do not consider the metabolic requirements, leading to inefficient serotonin synthesis and undesirable side effects due to acute administration of high doses, which can overload the serotonin-conversion pathway.
Innovation Solution
Manufacturing double-layer tablets with a 'fast' release layer containing 5-HTP for immediate release and a 'retarded' release layer containing Trp for progressive release, achieving a controlled and time-concentration-dependent release profile, avoiding fortuitous release and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If high doses of Trp or 5-HTP are administered to achieve rapid therapeutic response, then the speed of therapeutic action is improved, but the harmful side effects increase due to overloading the serotonin-conversion pathway
Solution Approach 1:
The patent divides the single-dose administration into multiple smaller doses administered at different times. The controlled-release formulation releases 5-HTP and Trp in a staged manner, with initial rapid release followed by sustained slower release, preventing the overload of the serotonin-conversion pathway while maintaining therapeutic efficacy over time.
Solution Approach 2:
The patent implements periodic administration of Trp/5-HTP at optimized intervals (e.g., every 8-12 hours) rather than continuous high-dose administration. This periodic dosing allows the enzymatic conversion pathway to process the substrate without overload, reducing side effects while maintaining steady serotonin precursor levels.
2Reliability
If Trp is administered in sufficient quantities to ensure adequate serotonin synthesis, then the therapeutic efficacy is improved, but the loss of Trp to alternative metabolic pathways increases
Solution Approach 1:
The patent provides a preliminary supply of 5-HTP (the direct precursor of serotonin) before administering Trp. This ensures that when Trp is available, the enzymatic pathway is already primed and can efficiently convert it to serotonin, reducing the shunting of Trp to alternative pathways like kynurenine metabolism.
Solution Approach 2:
The patent optimizes the concentration and timing parameters of Trp and 5-HTP administration. By controlling the release rate and maintaining specific concentration ranges, the patent ensures that the serotonin-synthesis enzymes operate at optimal efficiency, maximizing Trp conversion to serotonin while minimizing loss to other metabolic pathways.
3Duration of action of stationary object
If controlled-release formulations are developed to maintain bioavailable Trp levels, then the duration of action is improved, but the device complexity increases
Solution Approach 1:
The patent employs composite pharmaceutical formulations combining Trp, 5-HTP, and various excipients with different release characteristics. These composite materials provide controlled release through the interaction of multiple components rather than requiring complex mechanical or electronic release mechanisms, achieving extended duration of action with manageable formulation complexity.
Data Source
AI summary
New controlled-release formulations containing tryptophan and/or its metabolites are described, as well as the process to obtain them in tablet forms suitable for oral administration in the treatment of pathologies or conditions related to serotonin deficiency in the Nervous System. The formulations are comprised in double-layer tablets, one layer containing 5-hyrohytryptophan released rapidly (phase “fast), the other layer containing tryptophan or 5-hydroxytryptophan, progressively released (“retarded”). The finished product is characterized by optimal differential release profile under physiological conditions. In all cases the release kinetics obtained is accurately time- and concentration-controlled, therefore avoiding fortuitous release of the active ingredients, and in clinical setting is free of undesirable side effects.